Skip to content | Change text size
 

Professor Susan A Charman

Photo of Associate Professor Susan Charman, Pharmaceutics

Professor of Pharmaceutics
Director, Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences

BS Florida State University (USA)
PhD University of Florida (USA)

Telephone: +61 3 9903 9626
Fax: +61 3 9903 9627
Email: susan.charman@pharm.monash.edu.au

Theme Leader, Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences

Research interests

  • The development, establishment and application of lead optimisation technologies to rapidly identify, design and select the best drug discovery candidates for further pre-clinical and clinical development
  • The specific application of lead optimisation strategies to discover and develop new drugs for neglected diseases (in particular malaria) and cancer

Representative publications

  1. Wang X, Creek DJ, Schiaffo CE, Dong Y, Chollet J, Scheurer C, Wittlin S, Charman SA, Dussault PH, Wood JK, Vennerstrom JL.  Spiroadamantyl 1,2,4-trioxolane, 1,2,4-trioxane, and 1,2,4-trioxepane pairs: realtionship between peroxide bond iron(II) reactivity, heme alkylation efficiency, and antimalarial activity. Bioorganic & Medicinal Chemistry Letters. 2009; 19:4542-4545.
  2. Gujjar R, Marwaha A, El MAzouni F, White J, White KL, Creason S, Shackleford D, Baldwin J, Charman WN, Buckner FS, Charman SA, Rathod PK, Phillips MA. Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. Journal of Medicinal Chemistry. 2009; 52(7):1864-1872.
  3. Creek D, Charman WN, Chiu FCK, Prankerd RJ, Vennerstrom JL, Charman SA, et.al. Relationship between antimalarial activity and heme alkylation for spiro- and dispiro-1,2,4-trioxolane antimalarials.Antimicrobial Agents and Chemotherapy. 2008;52(4):1291-1296.
  4. Zhou L, Alker A, Ruf A, Wang X, Chiu FCK, Charman SA, et.al. Chracterization of the two major CYP450 metabolties of ozonide (1,2,4-trioxolane) OZ277. Bioorganic & Medicinal Chemistry Letters. 2008;18:1555-1558.
  5. Kota J, Machavaram K, McLennan D, Edwards G, Porter CJH, Charman SA. Lymphatic absorption of subcutaneously administered proteins: influence of different injection sites on the absorption of darbepetin alfa using a sheep model.Drug Metabolism and Disposition. 2007;35(12):2211-2217.
  6. Creek D, Charman WN, Chiu FCK, Prankerd R, McCullough KJ, Charman SA, et.al.  Iron-Mediated Degredation Kinetics of Substituted Dispiro-1,2,4-trioxolane Antimalarials. Journal of Pharmaceutical Sciences. 2007;96(11), 2945-2956.
  7. Perry CS, Charman SA, Prankerd RJ, Chiu FCK, Scanlon MJ, Chalmers D, et.al. The binding interaction of synthetic ozonide antimalarials with natural and modified beta-cyclodextrins.J Pharm Sci. 2006;95:146-158.
  8. Perry CS, Chiu FCK, McIntosh KA, Prankerd RJ, Charman WN, Charman SA. Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin. J Pharm Sci. 2006; 95:256-267.
  9. Perry CS, Charman SA, Prankerd RJ, Chiu FCK, Dong Y, Vennerstrom JL, et.al.  Chemical kinetics and aqueous degradation pathways of a new class of synthetic ozonide antimalarials.J Pharm Sci. 2006;95:737-747.
  10. Katneni K, Charman SA, Porter CJH. Permeability assessment of poorly water soluble compounds under solubilising conditions: The reciprocal permeability approach. J Pharm Sci. 2006;95:2170-2185.
  11. McLennan DN, Porter CJH, Edwards GA, Heatherington AC, Martin SW, Charman SA. The absorption of darbepoetin alfa occurs predominantly via the lymphatics following subcutaneous administration to sheep. Pharm Res. 2006;23:2060-2066.
  12. Dong Y, Chollet J, Matile H, Charman SA, Chiu F, Charman WN, et.al.Spiro and Dispiro-1,2,4-Trioxolanes as Antimalarial Peroxides: Charting a Workable Structure - Activity Relationship Using Simple Prototypes. Journal of Medicinal Chemistry. 2005; 48:4953-4961.
  13. McLennan D, Porter CJH,  Charman SA.  Subcutaneous Drug Delivery and the Role of the Lymphatics.Drug Discovery Today: Technologies. 2005;2(1):89-96.
  14. Creek D, Chiu F, Prankerd R, Charman SA, Charman WN. Kinetics of Iron-Mediated Artemisinin Degradation: Effect of Solvent Composition and Iron Salt.Journal of Pharmaceutical Sciences. 2005;94:1820-1829.
  15. McLennan DN, Porter CJH, Edwards GA, Martin SW, Heatherington AC, Charman SA. Lymphatic absorption is the primary contributor to the systematic availability of epoetin alfa following subcutaneous administration to sheep.J Pharmacol Exp Ther. 2005;313:345 -351.
  16. Vennerstrom JL, Arbe-Barnes S, Brun R, Charman SA, Chiu FCK, Chollet J, et.al.Identification of an antimalarial synthetic trioxolane drug development candidate.Nature. 2004;430:900-904.
  17. Charman SA, DN McLennan, GA Edwards, CJH Porter. Lymphatic absorption is a significant contributor to the subcutaneous bioavailability of insulin in a sheep model. Pharm Res. 2001; 18(11):1620-1626.
  18. Charman SA, Mason KL, Charman WN. Techniques for assessing the effects of pharmaceutical excipients on the aggregation of porcine growth hormone. Pharm Res. 1993; 7:954-962.
  19. Charman SA, Charman WN, Wilson TD, Rogge MC, Dutko FJ, Pouton CW. Self-emulsifying drug delivery systems: Formulation and biopharmaceutic evaluation of an investigational lipophilic compound. Pharm Res. 1992; 9:87-93.
  20. FitzGerald GA, Lupinetti M, Charman SA, Charman WN. Presystemic acetylation of platelets by aspirin: Reduction in the rate of drug delivery to improve biochemical selectivity for thromboxane A2. J Pharmacol Exp Ther. 1991; 259:1043-1049.

External appointments

  • Member of the Pharmaceutical Industry Working Group, Australia
  • Member of the Expert Discovery Advisory Committee, UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), Geneva, Switzerland
  • Member of the Scientific Advisory Board, Consortium of Parasitic Drug Development (CPDD), University of North Carolina, USA
  • Member of the Management Committee, Biopharmaceutical Formulation Centre, Melbourne, Austraila
  • Member of the International Affairs Committee, American Association of  Pharmaceutical Scientists